Open-house rebate agreement for Solifenacin/Tamsulosin
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Solifenacin/Tamsulosin (ATC-Code nach WHO: G04CA53)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...
Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 29, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2028
- Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Solifenacin/Tamsulosin.
- Open-House participation model with no individual contract negotiations.
Show full summary
This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Solifenacin/Tamsulosin (ATC G04CA53) led by AOK PLUS. Any interested pharmaceutical company may join during the participation period if it meets and accepts the stated conditions. No individual negotiations or supply exclusivity apply. The contract term ends no later than 2028-02-29. Participation is handled electronically via DTVP project space, but the submission method is described as technically constrained and not fully consistent across the notice data.
Risks
The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...
Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of the cited German pharmaceutical law provisions for the offered medicinal product.
- The bidder must accept the participation conditions and the rebate agreement terms.
Eligibility
- The bidder must submit the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Solifenacin/Tamsulosin
Non-exclusive supply contract for pharmaceutical rebate agreements concerning Solifenacin/Tamsulosin (ATC G04CA53). The lot is an Open-House model, so all interested pharmaceutical companies may participate if they satisfy the participation conditions. Place of performance is Germany, specifically Dresden in Saxony/Thuringia context as stated in the notice data.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Solifenacin/Tamsulosin (ATC-Code nach WHO: G04CA53)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 22 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 856012-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...
Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications